Abstract
The following study was performed to further characterize a primate model of asthma using classes of drugs that target allergy (pyrilamine, cetirizine), are bronchodilators for the treatment of asthma (salbutamol, salmeterol) or are anti-inflammatory (dexamethasone). These drugs were examined for their ability to inhibit acute, antigen-induced bronchoconstriction, the development of airway hyperresponsiveness (AHR) and the infiltration of leukocytes into the lungs of atopic cynomolgus monkeys (Macaca facsicularis) using a 10-day, multiple antigen (Ag) challenge protocol. All compounds except dexamethasone and cetirizine significantly (p<0.05) reduced acute, Ag-induced bronchoconstriction (salbutamol: 74.2%, salmeterol: 52.6%%, pyrilamine: 62.4% inhibition) compared to vehicle control trials. Only dexamethasone and salmeterol prevented the development of AHR to methacholine challenge by 90.4±6.81% and 85.7±5.61% respectively. Dexamethasone significantly reduced the Ag-induced increase in BAL eosinophils by 85.9±8.53%. Cetirizine reduced the eosinophil response in 5 of 6 monkeys and salmeterol demonstrated a trend towards reduced eosinophil increases after multiple Ag challeng, but neither of these were statistically significant. These results further illustrate the utility of this model in predicting compound effects against several relevant functional endpoints that are consistent with the effects of similar classes of compounds in humans.
Similar content being viewed by others
References
Patterson R. Animal models demonstrating respiratory responses to inhalant antigens. Yale J Biol Med 1968;40:495–500.
Kosch PC, Gillespie JR, Berry JD. Respiratory mechanics in normal bonnet and rhesus monkeys. J Appl Physiol 1979;46:166–75.
Krell RD. Airway hyperreactivity to pharmacologic agents in rhesus monkeys cutaneously hypersensitive to ascaris antigen. Life Sci 1976;19:1777–82.
Gundel RH, Gerritsen ME, Gleich GJ, Wegner CD. Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. J Appl Physiol 1990;68:779–86.
Gundel RH, Wegner CD, Letts LG. Antigen-induced acute and late-phase responses in primates. Am Rev Respir Dis 1992; 146:369–73.
Turner CR, Smith WB, Andersen CJ, Swindell AC, Watson JW. Leukotriene D4 Receptor Antagonism Reduces Airway Hyperresponsiveness in Monkeys. Pulmon Pharmacol 1994;7: 49–58.
Turner CR, Andresen CJ, Smith WB, Watson JW. Effect of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 1994;149:1153–9.
Gundel RH, Torcellinini CA, Clarke CC, Desai SN, Lazer ES, Wegner CD. The effects of a 5-lipoxygenase inhibitor on antigen-induced mediator release, late phase bronchoconstriction and cell infiltrates in primates. Adv in Prostagland Thromb Leukotr Res 1991;88:1407–11.
Gundel RH, Letts LG, Wegner CD. The role of platelet activating factor in airway inflammation, airway hyperresponsiveness and pulmonary function in monkeys. Ann NY Acad Sci 1991;629:205–16.
Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990;247:456–9.
Mann KV, Crowe JP, Tietze KJ. Non-sedating histamine H1 receptor antagonists. Clin Pharm 1989;8:331–44.
Redier H, Chenez P, DeVos C, Rifai N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992;90:215–24.
Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993;91:1189–97.
Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled β2 adrenoreceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988;43:674–8.
Sanjar S, McCabe PJ, Reynolds LH, Johnson M. Salmeterol inhibits antigen-induced eosinophil accumulation in the guinea pig lung. Fund Clin Pharmacol 1991;5:402.
Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669–74.
Wegner CD, Jackson AC, Berry JD, Gillespie JR. Dynamic respiratory mechanics in monkeys measured by forced oscillations. Respir Physiol 1984;55:47–61.
Osborn RR, Hay DWP, Wasserman MA, Torphy TJ. SK&F 104353, a selective leukotriene receptor antagonist, inhibits leukotriene D4- and antigen-induced bronchoconstriction in Cynomolgus monkeys. Pulmon Pharmacol 1992;5:153–7.
Rafferty P, Ghosh SK, DeVos C, Patel KR. Effect of oral and inhaled cetirizine in allergen induced bronchoconstriction. Clin Exp Allergy 1993;23:528–31.
Pelikan Z. Effects of cetirizine (CZ) on the immediate (INR) and late nasal response (LNR) and on the eosinophils in the nasal secretions (NS). J Allergy Clin Immunl 1993;91:193.
Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. 1990;336:1338–42.
Gundel RH, Kinkade P, Torcellini CA, Clarke CC, Watrous J, Desai S, et al. Antigen-induced mediator release in primates. Am Rev Respir Dis 1991;144:76–82.
Pepys J, Davies RJ, Breslin BX, Hendricks DJ. The effects of inhaled beclomethasone dipropionate (Becotide) and sodium cromoglycate on asthma reactions to provocation tests. Clin Allergy 1974;4:13–24.
Chung KF. Pharmacology of airway inflammation in asthma. Lung 1990;Suppl:132–41.
Rieder H, Chanez P, De Vos C, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992;90:215–24.
Townley RG, Okada C. Use of cetirizine to investigate non H1 effects of second generation antihistamines. Ann Allergy 1992; 68:190–6.
Morley J, Sanjar S, Newth C. Viewpoint: untoward effects of beta-adrenoreceptor agonists in asthma. Eur Resp J 1990;3: 228–33.
Lofdahl CG, Chung KF. Long-acting β2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Resp J 1991;4:218–26.
Laitinen LA, Laitinen A, Haahtela T. Treatment of eosinophilic airway inflammation with inhaled corticosteroid, budesonide, in newly diagnosed asthmatic subjects. Eur Respir J 1991;4:342–7.
Josephs LK, Gregg I, Mullee MA, Campbell MJ, Holgate ST. A longitudinal study of baseline FEV1 and bronchial responsiveness in patients with asthma. Eur Respir J 1992;5: 32–9.
Ramsdale EH, Otis J, Kline PA, Gontovnick LS, Hargreave FE, O'Byrne PM. Prolonged protection against methacholineinduced bronchoconstriction by the inhaled β2-agonist formoterol. Am Rev Respir Dis 1991;143:998–1001.
Wood-Baker R, Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993;91:1005–14.
Spencer CM, Faulds D, Peters DH. Cetirizine. A Reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993;46:1055–80.
Baroody FM, Cruz AA, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol 1992;90:373–6.
Author information
Authors and Affiliations
Additional information
accepted by M. J. Parnham
Rights and permissions
About this article
Cite this article
Turner, C.R., Andresen, C.J., Smith, W.B. et al. Characterization of a primate model of asthma using anti-allergy/ anti-asthma agents. Inflamm Res 45, 239–245 (1996). https://doi.org/10.1007/BF02259610
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02259610